Abstract: The present invention provides a NDV mutant that is suited as a marker vaccine strain. The NDV mutant is not able to express an immunodominant epitope of the nucleoprotein (NP).
Type:
Grant
Filed:
October 30, 2001
Date of Patent:
July 4, 2006
Assignee:
Akzo Nobel N.V.
Inventors:
Teshome Mebatsion, Marcus Josephus Marie Koolen
Abstract: The present invention provides soluble protein solutions, free of suspended particles in high yield. More particularly, the current invention provides a method for removing suspended particles from soluble protein solutions by filtering the soluble protein solution through highly purified diatomaceous earth.
Abstract: The invention relates to the use of novel peptides in a peptide induced tolerance therapy to prevent autoimmune disorders and in particular their use in treatment of chronic destruction of articular cartilage. The invention furtermore embraces pharmaceutical compositions comprising said peptides and a diagnostic method for the detection of autoreactive T cells in a test sample.
Type:
Grant
Filed:
July 16, 1999
Date of Patent:
November 15, 2005
Assignee:
Akzo Nobel N.V.
Inventors:
Gijsbertus Franciscus Maria Verheijden, Anna Maria Helena Boots
Abstract: The invention is directed to methods for purifying Troponin I, particularly recombinant Tropnin I produced in a bacterial expression system. Recombinant Tropnin I can be advantageously purified after reversibly protecting the free sulfhydryl groups, e.g., by forming sulfates. In a specific example, Tropnin I reacted with sodium tetrafhionate yielded sulfitolyzed Tropnin I, which was purified by chromatography on an anion exchanger, followed by hydrophobic interaction chromatography. Facile deprotection of the sulfhydryl groups yields a highly purified product ready for refolding.
Type:
Grant
Filed:
November 30, 2001
Date of Patent:
January 11, 2005
Assignee:
Akzo Nobel NV
Inventors:
Gregory Conn, Brian Reardon, Xianfang Zeng, Chenming Zhang
Abstract: The present invention relates to vaccines comprising antiserum raised against a flagellaless Campylobacter strain for the prevention of Campylobacter colonisation in animals. The invention also relates to antigenic Campylobacter proteins visible in a Western blot of Campylobacter jejuni protein after incubation of said Western blot with antibodies against a flagellaless mutant of Campylobacter jejuni and not visible after incubation of said blot with antibodies against wild type Campylobacter jejuni, and to their use in vaccines and the manufacturing thereof. The invention further relates to vaccines comprising such proteins and antibodies against such proteins. The invention further relates to the use of such Campylobacter proteins and to antiserum and antibodies raised against Campylobacter antigens for the preparation of vaccines. Finally, the invention relates to methods for the preparation of such vaccines.
Type:
Grant
Filed:
April 7, 2000
Date of Patent:
September 7, 2004
Assignee:
Akzo Nobel N. V.
Inventors:
Antonius Arnoldus Christiaan Jacobs, Johannes Franciscus van den Bosch, Petrus Johannes Maria Nuijten